STOCK TITAN

BioVie, Inc. - $BIVI STOCK NEWS

Welcome to our dedicated page for BioVie news (Ticker: $BIVI), a resource for investors and traders seeking the latest updates and insights on BioVie stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioVie's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioVie's position in the market.

Rhea-AI Summary
BioVie Inc. announces completion of Phase 3 study for NE3107 in Alzheimer's Disease patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.62%
Tags
-
Rhea-AI Summary
BioVie's lead drug candidate aims to treat neurodegenerative disease by targeting inflammation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.12%
Tags
none
-
Rhea-AI Summary
BioVie Inc. to participate in Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.06%
Tags
conferences
Rhea-AI Summary
BioVie presents preliminary baseline data from Phase 3 trial of NE3107 for Alzheimer's Disease at ANA annual meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
-
Rhea-AI Summary
BioVie Inc. hosts virtual KOL event ahead of Phase 3 results in Alzheimer's Disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
none
-
Rhea-AI Summary
BioVie to host virtual KOL event on NE3107 ahead of Phase 3 results in Alzheimer’s Disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.61%
Tags
conferences
Rhea-AI Summary
BioVie presents new data on NE3107 in the treatment of Parkinson's Disease at MDS Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
-
Rhea-AI Summary
RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Soligenix, Inc. (Nasdaq:SNGX) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, August 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
-
News
Rhea-AI Summary
BioVie Inc. provides an update on the progress of its Phase 3 trial for NE3107 in Alzheimer's Disease (AD). The company reports positive results from a Phase 2 exploratory biomarker study, showing enhanced cognition and reductions in inflammation and biomarkers. Treatment with NE3107 led to >50% reductions in DNA methylation of 400 CpGs, which were significantly correlated with clinical improvements. Over 3,000 significant correlations were found linking reductions in DNA methylation and cognitive, biomarker, and neuroimaging endpoints.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
none
BioVie, Inc.

Nasdaq:BIVI

BIVI Rankings

BIVI Stock Data

27.32M
22.51M
43.25%
4.49%
2.69%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CARSON CITY

About BIVI

biovie inc. (otc pink: bivi) is developing novel drug therapies for life-threatening complications of chronic liver disease. our initial target is ascites, which can occur in patients with advanced cirrhosis due to hepatitis, nash (non-alcoholic steatohepatitis), or alcoholism. ascites affects about 100,000 americans and carries an estimated 40% mortality rate within two years of being diagnosed. the company’s new drug candidate biv201 is about to enter a phase 2 clinical trial in the us. it’s based on a drug (terlipressin) not yet available in the us, but approved in about 40 countries for treating related complications of liver cirrhosis. the fda has never approved a drug to treat ascites and there is a significant unmet medical need for our novel therapy, which has orphan drug status. biovie has attracted funding from strategic investors including aspire capital, cuong do, the global strategy lead for samsung, and hari kumar, founder of adheron therapeutics which he sold to roche fo